Blincyto
| Chemical Name | blinatumomab |
| Dosage Form | Injection (intravenous; 35 mcg) |
| Drug Class | CD19-directed CD3 T-cell engagers |
| System | Multiple |
| Company | Amgen |
| Approval Year | 2014 |
Indication
- For the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
- For the treatment of adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.